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Background: We assessed the effect of once-weekly semaglutide and once-daily liraglutide 
on kidney outcomes in type 2 diabetes (T2D). 
Methods: Pooled (N=12,637) and by-trial data from SUSTAIN 6 (N=3297) and LEADER 
(N=9340) were assessed for albuminuria change, annual slope of estimated glomerular 
filtration rate (eGFR) change, and time to persistent eGFR reduction (30%, 40%, 50%, and 
57%) from baseline. 
Results: The median follow-up durations were 2.1 and 3.8 years for SUSTAIN 6 and 
LEADER, respectively. In the pooled analysis, semaglutide/liraglutide lowered albuminuria 
from baseline to 2 years post-randomization by 24% versus placebo (95% confidence interval 
[CI] [20%,27%], p<0.001). Significant reductions were also observed in by-trial data
analyses (p<0.001 for all), the largest being with semaglutide 1.0 mg: 33% (95% CI
[24%,40%], p<0.001) at 2 years.
With semaglutide 1.0 mg and liraglutide, eGFR slope decline was significantly slowed by
0.87 and 0.26 mL/min/1.73 m2/year (p<0.0001 and p<0.001), respectively, versus placebo.
Effects appeared larger in those with baseline eGFR <60 versus >60 mL/min/1.73m2
(pinteraction=0.06 and 0.008 for semaglutide 1.0 mg and liraglutide, respectively).
Semaglutide/liraglutide significantly lowered risk of persistent 40% and 50% eGFR
reductions versus placebo (hazard ratio [HR] 0.86, 95% CI [0.75,0.99], p=0.039, and HR
0.80, 95% CI [0.66,0.97], p=0.023, respectively). Similar, non-significant, directional results
were observed for 30% and 57% eGFR reductions (HR 0.92, 95% CI [0.84, 1.02], p=0.10,
and HR 0.89, 95% CI [0.69, 1.13], p=0.34). In those with baseline eGFR
30−<60mL/min/1.73m2, the likelihood of persistent reduction for all thresholds was
increased, ranging from a HR 0.71 for 30% reduction (95% CI [0.59,0.85], p=0.0003,
pinteraction=0.017) to 0.54 for 57% reduction (95% CI [0.36,0.81], p=0.003, pinteraction=0.035).
Conclusions: In patients with T2D, semaglutide/liraglutide offered kidney-protective effects,
which appeared more pronounced in those with pre-existing chronic kidney disease.
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Non-standard Abbreviations and Acronyms: 
CVOT: cardiovascular outcome trial 
CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration  
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What is new?  
• Current data suggest a kidney-protective effect with glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) driven primarily by beneficial albuminuria outcomes, but
definitive data on more severe kidney outcomes were lacking.
• In this analysis of the SUSTAIN 6 and LEADER trials, we demonstrated the benefit
of using once-weekly semaglutide and once-daily liraglutide on a number of clinically
important kidney outcomes: changes in albuminuria, annual slope of estimated
glomerular filtration rate (eGFR) change, time to persistent. proportional eGFR
reductions of 40% and 50% from baseline, and a composite endpoint (time from
randomisation to first occurrence of kidney failure/death or proportional eGFR
decline).
What are the clinical implications? 
• The results of this study suggest that the GLP-1 RAs semaglutide and liraglutide may
add to the kidney-protective treatment options available to people with type 2 diabetes
(T2D) and diabetic kidney disease (DKD).
• Further studies are required to investigate the full effect of GLP-1 RAs on primary
kidney endpoints in dedicated trials in DKD. SUSTAIN 6 and LEADER examined
kidney endpoints as secondary outcomes and enrolled a majority of patients without









Type 2 diabetes (T2D) is a major risk factor for the development and progression of chronic 
kidney disease, commonly referred to as diabetic kidney disease (DKD).1 Approximately 
50% of people with T2D will develop DKD in their lifetime, and about half of kidney failure 
cases are ascribed to diabetes.1, 2 Since the global burden of T2D is increasing,3 so too is the 
prevalence of kidney failure. Accordingly, the prevalence of kidney failure is predicted to 
exceed five million people by 2030.4  
People with DKD have a high risk of cardiovascular morbidity and mortality, and 
generate increased costs associated with their treatment.5 A limited number of treatments 
have been shown to lower this risk. Thus, it is important to identify treatments that reduce the 
risk of cardiovascular complications and of progression to kidney failure in people with 
DKD. 
Recent developments in the management of T2D have identified treatments that reduce the 
risk of DKD progression. In cardiovascular outcome trials (CVOTs), sodium-glucose 
cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 
RAs) have lowered the risk of major adverse cardiovascular events.6-12 Moreover, secondary 
kidney outcomes in these CVOTs have suggested kidney benefits.6-16 Recently, in the first 
designated T2D kidney outcome trials, the SGLT-2is canagliflozin and dapagliflozin were 
shown to substantially lower the risk of hard kidney outcomes compared with placebo 
(patients with and without T2D were included in the latter trial).17, 18  
Accordingly, the aim of this post hoc analysis was to further evaluate the effect of 
once-weekly semaglutide and once-daily liraglutide therapy on a broad range of clinically 
important kidney outcomes, including changes in albuminuria, estimated glomerular filtration 










Data sharing statement 
De-identified individual participant data, study protocol, and redacted Clinical Study Report 
will be available according to Novo Nordisk data sharing commitments. The data will be 
made available permanently after research completion, and approval of product and product 
use in both the EU and US. Data will be shared with bona fide researchers submitting a 
research proposal requesting access to data and for use as approved by the Independent 
Review Board according to the IRB Charter (see novonordisk-trials.com). Access request 
proposal form and access criteria can be found at novonordisk-trials.com. The data will be 
made available on a specialized SAS data platform. 
Trial designs and patients  
SUSTAIN 6 (NCT01720446) and LEADER (NCT01179048) were randomized, double-
blinded, placebo-controlled trials. Detailed methods of both trials have been published 
previously.6, 7 The two trials included patients with T2D at high risk of cardiovascular events 
and with glycated hemoglobin (HbA1c) level ≥7%. In the SUSTAIN 6 trial, patients were 
randomized to once-weekly semaglutide 0.5 mg subcutaneously (s.c.), once-weekly 
semaglutide 1.0 mg s.c, or matching placebo for 2 years. In LEADER, patients were 
randomized to once-daily liraglutide up to 1.8 mg s.c. or matching placebo for 3.5 to 5 years 
(median 3.8 years). The primary outcome in both trials was major adverse cardiovascular 
events, consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular 
death. Kidney endpoints were collected as secondary outcomes. Both cardiovascular and 
kidney outcomes were adjudicated by an external blinded event adjudication committee 
(EAC).6, 7   
In SUSTAIN 6, serum creatinine was collected at screening, randomization 
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of eGFR was performed using the Modification of Diet in Renal Disease (MDRD) 
equation.19 Urinary albumin-to-creatinine ratio (UACR) was collected at baseline and 
post-baseline at weeks 16, 30, 44, 56, 80, and 104.  
In LEADER, serum creatinine was collected at screening, randomization (baseline), 
and post-baseline at the 6-month visit, and then annually until last visit. Calculation of eGFR 
was performed using the MDRD equation.19 UACR was collected at baseline and 
post-baseline annually until last visit.  
Urinary albumin values below the lower limit of quantification (LLOQ) of 3 mg/g 
were imputed as 1.5 mg/g (LLOQ/2) in the calculation of UACR post hoc. Approximately 
17% of randomized patients had UACR values below LLOQ in both SUSTAIN 6 and 
LEADER at baseline.  
Subgroups 
We evaluated outcomes for the overall pooled population and according to pre-existing 
kidney disease, defined by baseline eGFR (using the MDRD formula) and albuminuria. 
Patients were stratified by baseline eGFR (eGFR ≥90 mL/min/1.73m2, 60–<90 
mL/min/1.73m2, 30–<60mL/min/1.73m2, or <30 mL/min/1.73m2) and albuminuria stage 
(normoalbuminuria [UACR <30 mg/g], microalbuminuria [UACR 30−300 mg/g], and 
macroalbuminuria [UACR >300 mg/g]). Effects of semaglutide and liraglutide versus 
placebo on albuminuria over time, average annual eGFR decline (slope), and the eGFR at the 
2-year visit were also evaluated in the populations treated with semaglutide 0.5 and 1.0 mg,
and liraglutide 1.8 mg, respectively.  
Outcomes 
We explored the effects of semaglutide in SUSTAIN 6 and liraglutide in LEADER, 
compared with placebo, on clinically important kidney outcomes,20 including: change in 








and presented as estimated geometric mean ratio between treatment and placebo), annual 
change in eGFR from baseline (total slope), and time to persistent 30%, 40%, 50%, and 57% 
eGFR  (57% being equivalent to doubling of creatinine) reductions from baseline, defined by 
time to first occurrence from randomization of the relevant reduction confirmed by a 
subsequent measurement. If no subsequent visit was performed, the confirmation was 
omitted. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was 
used to calculate the eGFR used in the total slope analysis. 
Other outcomes included a composite of time from randomization to first occurrence 
of kidney death, need for maintenance kidney replacement therapy, or first occurrence of a 
reduction in eGFR of 40%, 50%, or 57% (each percentage analyzed separately with the first 
two components, to give three composite endpoints). We estimated total loss of eGFR over 2 
years from randomization for both trials according to treatment groups. We assessed these 
outcomes in the overall pooled population and in subgroups defined by UACR and eGFR at 
baseline, as defined above. Kidney failure and death, as components of the original secondary 
endpoints of both trials, were EAC-confirmed.6, 7  
Statistical analysis 
Data from all randomized patients in LEADER and SUSTAIN 6 were included from date of 
randomization to the end-of-follow-up visit. In the pooled analyses, both semaglutide 
treatment arms and the liraglutide treatment arm were pooled and compared with placebo. 
For the pooled analyses, the trial was used as a fixed effect. 
Effects of semaglutide and liraglutide by trial on albuminuria over time as compared 
with placebo were assessed using a mixed model for repeated measures (MMRM) with 
UACR as dependent variable (which was log-transformed due to the non-normal 
distribution), with treatment and visits as fixed factors, and baseline UACR (log-transformed) 
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An unstructured covariance matrix for repeated measures was used. Least square means, 
differences and 95% confidence interval (CI) between treatments was then back-transformed 
to the original scale. Due to the different trial durations of LEADER and SUSTAIN 6, 
treatment ratios were evaluated at 2 years from randomization to align comparisons of both 
trials. Pooled analyses were done using the same model with trial also included as an 
additional factor.  
Slope analyses of eGFR were performed using a random-slope model by trial, with 
change from baseline as dependent variable and baseline value and time (in years) as 
covariate, and treatment as a fixed factor and the interaction between treatment and time. The 
intent-to-treat populations were used. Changes from baseline were assessed between each 
visit and used as the repeated measure, with the time from randomization as the underlying 
continuous time scale for the slope analyses. Patient-specific intercepts and time as random 
effects assuming a bivariate normal distribution for these effects were included in the model. 
Analyses by subgroups were performed by including the respective subgroups as a fixed 
factor and the interaction with treatment.  
Time to first event analyses were performed using Cox proportional hazard models, 
with pooled treatment as a fixed factor and stratified by trial. Patients without respective 
events were censored at death or end of follow-up, whichever came first. Time to persistent 
reduction of eGFR from baseline (30%, 40%, 50%, and 57%) was analyzed independently 
from each other. Subgroup analyses were performed by including subgroup as a fixed factor 
and the interaction between subgroup and treatment. A quadratic spline Cox regression model 
was also used to analyse the time to persistent reduction endpoints (30%, 40%, 50%, 57%), 
showing the hazard ratios (HRs) between the treatments (pooled GLP-1 RAs vs placebo) 








An I2 test was used to measure the heterogeneity between the two trials when 
assessing the effect of semaglutide and liraglutide versus placebo on the annual eGFR slope 
at 2 years visit in the overall population and subgroups with pre-existing DKD defined by the 
level of albuminuria and eGFR at baseline. 
No adjustment for multiplicity or missing values was performed. A significance level 
of 5% was used overall. Statistical analysis was performed with SAS version 9.4 (SAS 
Institute, Cary, NC, USA). 
Ethics 
Both studies received full approval by ethics committees/institutional review boards at each 
participating site (names and locations of sites available in the supplementary information of 
the primary publications of both trials6, 7), and were conducted according to the principles of 
the Declaration of Helsinki.21 All participants provided written informed consent prior to 
participation in trial-related activities.6, 7   
Role of the funding source 
The sponsor participated in the study design and management, analysis, and interpretation of 
data. Three of the authors of this manuscript are employees of the sponsor and, as such, were 
involved in the preparation, review, and approval of the manuscript. All authors had full 





A total of 12,637 patients were included in the pooled analysis (3297 from SUSTAIN 6 and 
9340 from LEADER), with 6316 patients in the combined semaglutide/liraglutide group 
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1.8 mg groups, respectively) and 6321 patients in the combined placebo group. The median 
durations of follow-up (post-randomization) were 2.1 and 3.8 years for SUSTAIN 6 and 
LEADER trials, respectively.6, 7 Patient characteristics according to albuminuria and eGFR 
and treatment allocation are presented in Table 1. At baseline, a total of 3063 (24.2%) 
patients had an eGFR <60 mL/min/1.73m2, and 4726 (38.2%) patients had elevated 
albuminuria, either microalbuminuria (27.0%) or macroalbuminuria (11.2%). 
Effects on albuminuria 
In the pooled analysis, semaglutide/liraglutide treatment lowered albuminuria from baseline 
to 2 years post-randomization by 24% (placebo-corrected geometric mean ratio of relative 
change from baseline) compared with placebo (95% CI [20%, 27%], p<0.001) (Figure 1). 
This was driven by data from liraglutide, given the larger number of patients from LEADER 
than from SUSTAIN 6. The magnitude of reduction, however, was modified by baseline level 
of albuminuria – normoalbuminuria (20%, 95% CI [15%, 25%]), microalbuminuria (31%, 
95% CI [25%, 37%]), and macroalbuminuria (19%, 95% CI [7%, 30%]); p for 
interaction=0.021 (Supplementary Figure 1). 
Both semaglutide and liraglutide lowered albuminuria compared with placebo (Figure 
1). At 2 years post-randomization, based on the placebo-corrected geometric mean ratios of 
relative change from baseline, semaglutide 0.5 mg lowered albuminuria by 20% compared 
with placebo (95% CI [10%, 28%], p<0.001) and the 1.0 mg dose lowered albuminuria by 
33% compared with placebo (95% CI [24%, 40%], p<0.001). At 2 years post-randomization, 
albuminuria was 23% lower in liraglutide-treated patients compared with placebo (95% CI 
[18%, 27%], p<0.001). The effect of the semaglutide 1.0 mg dose was statistically greater 
than liraglutide (p=0.024) at 2 years post-randomization.  








The average slope in eGFR change from baseline was comparable in the placebo arms of 
SUSTAIN 6 (average −1.92, 95% CI [−2.18, −1.67] mL/min/1.73m2/year) and LEADER 
(average −1.98, 95% CI [−2.10, −1.87] mL/min/1.73m2/year) in the overall population, and 
this was broadly consistent at different levels of baseline kidney function (Figure 2).  
In the overall population, patients randomized to semaglutide 0.5 mg had a non-
significant reduction in eGFR slope versus placebo (difference 0.33 mL/min/1.73m2/year, 
p=0.14), whereas randomization to semaglutide 1.0 mg slowed kidney function loss by 0.87 
mL/min/1.73m2/year versus placebo (p<0.0001) (Figure 2). Kidney function in patients 
randomized to liraglutide declined an average of 0.26 mL/min/1.73m2/year slower compared 
with placebo (p<0.001). 
Baseline eGFR was found to impact the effects of semaglutide and liraglutide on 
eGFR slope, with the largest effect observed in patients receiving semaglutide 1.0 mg with an 
eGFR <60 mL/min/1.73m2/year at baseline. Patients in this subgroup lost 1.62 
mL/min/1.73m2/year less kidney function versus those receiving placebo, whereas those with 
baseline eGFR ≥60 mL/min/1.73m2/year lost 0.63 mL/min/1.73m2/year less versus placebo 
(p<0.001; p for interaction =0.06). The difference was 0.67 vs 0.21 mL/min/1.73m2/year (p 
for interaction =0.37) for patients randomized to semaglutide 0.5 mg with baseline eGFR <60 
or >60 mL/min/1.73m2/year, respectively. Patients receiving liraglutide with baseline eGFR 
<60 mL/min/1.73m2 lost 0.67 mL/min/1.73m2/year less kidney function than those receiving 
placebo, while those with baseline eGFR ≥60 mL/min/1.73m2 lost 0.15 mL/min/1.73m2/year 
(p for interaction =0.008) (Figure 2). 
The results were similar when the total loss of kidney function over 2 years post-
randomization of all treatments was considered (Supplementary Figure 2).  
The effect of semaglutide on eGFR slope compared with placebo was not clearly 









compared with placebo ranged from 0.59 mL/min/1.73m2 (95% CI [−0.76, 1.94] 
mL/min/1.73m2) in the subgroup with normoalbuminuria to 0.29 mL/min/1.73m2 (95% CI 
[−2.16, 2.74] mL/min/1.73m2) in the subgroup with macroalbuminuria, p for interaction 
=0.98) at 2 years post-randomization. Semaglutide 1.0 mg effects on eGFR slope compared 
with placebo ranged from 1.48 mL/min/1.73m2 (95% CI [0.15, 2.80] mL/min/1.73m2) in the 
subgroup with normoalbuminuria to 2.33 mL/min/1.73m2 (95% CI [−0.19, 4.85] 
mL/min/1.73m2) in the subgroup with macroalbuminuria, p for interaction =0.84). The effect 
of liraglutide on eGFR slope compared with placebo appeared to be modified by the degree 
of albuminuria at baseline, with eGFR slope differences ranging from 0.20 mL/min/1.73m2 
(95% CI [−0.17, 0.58] mL/min/1.73m2) with normoalbuminuria to 1.64 mL/min/1.73m2 
(95% CI [0.68, 2.60] mL/min/1.73m2) with macroalbuminuria at 2 years post-randomization 
(p for interaction =0.023) (Supplementary Figure 2). 
Effect on persistent reduction in eGFR 
The overall effect of semaglutide/liraglutide (pooled) versus placebo on the risk of persistent 
reductions in eGFR using a range of clinically relevant thresholds is shown in Figure 3. In the 
overall population, persistent 40% and 50% reductions in eGFR occurred less frequently in 
patients receiving semaglutide/liraglutide compared with placebo (HR 0.86, 95% CI [0.75, 
0.99], p=0.039 and HR 0.80, 95% CI [0.66, 0.97], p=0.023, respectively; Figure 3). The risk 
of reaching a persistent 30% eGFR reduction (HR 0.92, 95% CI [0.84, 1.02], p=0.10) or a 
persistent 57% reduction (HR 0.89, 95% CI [0.69, 1.13], p=0.34) was not significantly 
reduced but showed similar directional results (Figure 3). 
In subgroups of patients with an eGFR 30–<60 mL/min/1.73m2 at baseline, persistent 
reduction in eGFR for all thresholds occurred in fewer patients in the semaglutide/liraglutide 
group compared with the placebo group, with a trend to greater effect sizes as eGFR 
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values were as follows: 30% reduction: 0.71 (0.59, 0.85), p=0.0003 (14.4% vs 19.2%); 40% 
reduction: 0.67 (0.52, 0.86), p=0.0017 (7.7% vs 11.0%); 50% reduction: 0.56 (0.40, 0.78), 
p=0.0006 (4.0% vs 6.8%); 57% reduction: 0.54 (0.36, 0.81), p=0.003 (2.6% vs 4.6%) (Figure 
3). The effect sizes appeared larger in subgroups of patients with eGFR 30−<60 
mL/min/1.73m2 at baseline compared with other subgroups (eGFR ≥90, 60−<90, and <30 
mL/min/1.73m2 at baseline), especially for 30% and 57% reduction thresholds (p for 
interaction =0.017 and 0.035, respectively) (Figure 3). On a continuous eGFR scale, the 
treatment effect associated with semaglutide/liraglutide vs placebo increased as baseline 
eGFR decreased (Supplementary Figure 3).  
The results were broadly consistent for subgroups based on baseline albuminuria 
(Figure 4), with separately statistically significant reductions in the risk of persistent 30%, 
40%, and 50% reductions in eGFR with semaglutide/liraglutide compared with placebo in 
subgroups of patients with macroalbuminuria (HRs ranged from 0.78, 95% CI [0.66, 0.92], 
p=0.004] for 30% reduction in eGFR to 0.77, 95% CI [0.60, 1.00], p=0.050] for 50% 
reduction in eGFR) and micro- or macroalbuminuria at baseline (HRs ranged from 0.85, 95% 
CI [0.76, 0.97], p=0.013 for 30% reduction in eGFR to 0.76, 95% CI [0.61, 0.95], p=0.016 
for 50% reduction in eGFR).  
Similar patterns were observed in subgroups of patients stratified based on a 
combination of baseline eGFR and albuminuria criteria (Supplementary Figure 4). The effect 
of semaglutide/liraglutide therapy on persistent reduction in eGFR for all thresholds appeared 
to be larger in subgroups of patients with eGFR 30–<60 mL/min/1.73m2 and micro- or 
macroalbuminuria at baseline than in subgroups with baseline eGFR of ≥60 mL/min/1.73m2
or normoalbuminuria, as well as subgroups with eGFR <30 mL/min/1.73m2 and micro- or 








When persistent reductions in eGFR were combined with kidney failure and kidney 





This post hoc analysis comprising 12,637 patients with T2D suggests that semaglutide and 
liraglutide have kidney-protective effects. Both semaglutide and liraglutide lowered 
albuminuria, slowed eGFR decline, and reduced the risk of substantial loss of kidney function 
at different thresholds. The effects of semaglutide and liraglutide on kidney function appear 
to be greater in subgroups of patients with pre-existing kidney disease, defined by reduced 
eGFR, increased albuminuria, or the combination of both. The data also suggest differences 
between agents, with the largest magnitude of protective effects observed for semaglutide 1.0 
mg. 
The likelihood of a kidney-protective effect with GLP-1 RA therapy is also supported 
by the results of other studies. In the AWARD-7 trial, dulaglutide was found to slow eGFR 
decline compared with insulin glargine in people with advanced chronic kidney disease,22 
with identical control of HbA1c in both groups. Moreover, dulaglutide also reduced the risk of 
substantial loss of kidney function compared with placebo in the REWIND trial, which 
examined kidney outcomes as key secondary endpoints.9 The ELIXA23 and EXSCEL24 trials 
monitored kidney outcomes only as adverse events and failed to demonstrate benefits for 
kidney function per se, despite moderate lowering albuminuria or lower incidence of new 
microalbuminuria with lixisenatide and exenatide, respectively. In a post hoc analysis of 
EXSCEL, the positive effect of exenatide on the eGFR slope was more pronounced in people 
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post hoc analysis, also reduced composites of either 40% or 30% eGFR decline and kidney-
replacement therapy.24 Variability in effects of GLP-1 RAs on cardiovascular outcomes has 
also been demonstrated,13 further highlighting the inability to generalize effects across 
different members of the drug class at doses that generally lead to comparable lowering of 
HbA1c. These variable cardiovascular and kidney benefits may be due to differences in trial 
conduct or to the medicines or their degradation products potentially having favorable effects 
with human-based, but not exendin-based, GLP-1 RAs in T2D.13, 26  
The mechanisms for the potential protective effect of semaglutide and liraglutide on 
the kidneys are uncertain. Possible contributing mechanisms include: natriuresis, oxidative 
stress reduction, reduced inflammation and fibrosis, and hemodynamic effects.13, 27, 28 
Alternative possible mechanisms include the indirect modification of kidney risk through 
lowering glucose levels, body weight, and blood pressure.17, 29, 30 However, the latter indirect 
effects likely only play a minor role according to mediation analyses, and the effects on blood 
pressure are modest.22, 31, 32 In a recent post hoc analysis of the LEADER and SUSTAIN 6 
trials, HbA1c mediated 25% and 26% (respectively) of the kidney protective effect associated 
with liraglutide and semaglutide, whereas the mediatory effects of systolic blood pressure and 
body weight were lower at 9% & 22% and 9% & 0%, respectively.32 Additionally, a previous 
post hoc analysis of the LEADER trial demonstrated that baseline HbA1c did not influence 
the kidney-protective effect of liraglutide.15 As previously mentioned, dulaglutide and insulin 
lowered HbA1c to the same extent in the AWARD-7 trial. Despite this, patients receiving 
dulaglutide had a significantly lower eGFR decrease compared with insulin, again suggesting 
that HbA1c alone does not drive the kidney-protective effects observed with GLP-1 RAs.22 









The larger magnitude of effect of the semaglutide 1.0 mg dose compared with both the 
semaglutide 0.5 mg dose and liraglutide on both albuminuria and eGFR, along with likely 
benefits on substantial reductions in kidney function, suggests that this agent in particular 
might have an important role in protecting kidney function in diabetes. This may be 
especially relevant in people with existing DKD. Although these post hoc analyses of 
secondary outcomes are promising, a specific, sufficiently powered trial aiming to assess the 
effects of semaglutide/liraglutide on kidney outcomes in people with diabetes and kidney 
disease is needed and currently ongoing. The FLOW trial (ClinicalTrials.gov Identifier: 
NCT03819153) specifically addresses the question regarding slowing progression of DKD. 
The trial will enrol 3508 patients with T2D and kidney disease to either semaglutide 1.0 mg 
s.c. or matching placebo. The primary outcome is a composite of kidney failure (dialysis or 
transplantation, persistent eGFR <15 mL/min/1.73 m2), a persistent ≥50% reduction in eGFR, 
and kidney or cardiovascular death. FLOW will provide a definitive assessment of the kidney 
protection suggested in this analysis. In addition, kidney outcomes in patients treated with 
semaglutide will be investigated as secondary endpoints in both the SOUL trial 
(ClinicalTrials.gov Identifier: NCT03914326) and SELECT trial (ClinicalTrials.gov 
Identifier: NCT03574597).  
There are limitations and strengths in our analysis. The main strength is the incorporation of 
two large randomized clinical trials that prospectively defined adjudicated kidney outcomes 
as key secondary outcomes. However, there are also some limitations. This is an exploratory 
analysis and was not prespecified. The SUSTAIN 6 and LEADER trials were not originally 
powered to evaluate kidney outcomes and included patients with relatively low kidney risk at 
baseline. We did not take into account competing risk from terminal events, e.g. 
cardiovascular death, which could favor especially the liraglutide arm versus placebo, as for 









persistent reduction in eGFR was defined as the first occurrence of reduction confirmed by a 
subsequent measurement, patients with eGFR reduction whose subsequent eGFR could not 
be measured (either due to a fatal event or having an eGFR reduction at the last schedule 
visit) were included in the analysis. This has likely influenced the sustained eGFR reduction 
analysis (supplementary Table 1).  
In conclusion, this pooled analysis suggests a kidney-protective effect of semaglutide and 
liraglutide. This effect seems to be more pronounced in people with DKD. The FLOW trial 
will prospectively test the effect of semaglutide in this patient group and may identify an 
additional therapeutic strategy for people with T2D and kidney disease. 
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Table 1: Baseline Albuminuria and eGFR Characteristics by Treatment Group. 
Subgroups at baseline All/subtotal Semaglutide/liraglutide Placebo 
Total population 12,637 (100) 6316 (100) 6321 (100) 




















eGFR <60 mL/min/1.73m2 3063 (24.2) 1571 (24.9) 1492 (23.6) 
eGFR ≥60 mL/min/1.73m2 9574 (75.8) 4745 (75.1) 4829 (76.4) 
eGFR ≥90 mL/min/1.73m2 4268 (33.8) 2112 (33.4) 2156 (34.1) 
eGFR 60–<90mL/min/1.73m2 5306 (42.0) 2633 (41.7) 2673 (42.3) 
eGFR 30–<60 mL/min/1.73m2 2733 (21.6) 1400 (22.2) 1333 (21.1) 
eGFR <30 mL/min/1.73m2 330 (2.6) 171 (2.7) 159 (2.5) 
eGFR ≥60 mL/min/1.73m2 
and/or normoalbuminuria 10,719 (86.6) 5339 (86.2) 5380 (87.0) 
eGFR 30–<60 mL/min/1.73m2 
and micro- or macroalbuminuria 1402 (11.3) 723 (11.7) 679 (11.0) 
eGFR <30 mL/min/1.73m2 and 
micro- or macroalbuminuria 254 (2.1) 132 (2.1) 122 (2.0) 
eGFR <60 mL/min/1.73m2 and 
micro- or macroalbuminuria 1656 (13.4) 855 (13.8) 801 (13.0) 
*Number of people with UACR values that were collected and analyzed at baseline was used as the
denominator in calculating the percentages in all rows, apart from the first row. The percentage of
patients with UACR values out of the total number of patients was: all, 97.9%;
semaglutide/liraglutide, 98.1%; placebo, 97.8%. Data are n (%). eGFR, estimated glomerular filtration
rate; n, number of patients; UACR, urinary albumin-to-creatinine ratio; %, percentage of patients.Dow
nloaded from




Figure 1. Effects of OW Aemaglutide and OD Liraglutide Versus Placebo on 
Albuminuria Over Time. *Estimated geometric mean ratio calculated for each active 
treatment group versus the respective placebo group. Geometric mean values of albuminuria 
over time with semaglutide and liraglutide by trial as compared with placebo were estimated 
using a MMRM with an unstructured covariance matrix for repeated measures. UACR was 
included as a dependent variable (which was log-transformed) with treatment and visits as 
fixed factors, and baseline UACR as a covariate (log-transformed). Pooled analyses were 
done using the same model with trial also included as a fixed factor. CI, confidence interval; 
MMRM, mixed model for repeated measures; OD, once-daily; OW, once-weekly; UACR, 
urinary albumin-to-creatinine ratio. 
Figure 2. Effects of OW Semaglutide and OD Liraglutide Versus Placebo on Average 
Annual eGFR Decline (slope) in All Patients and According to Baseline eGFR. N is the 
number of patients whose samples/parameters were available at the point of analysis. Slope 
analyses performed on the intent-to-treat population. Slope analyses of eGFR were performed 
using a random-slope model by trial with change from baseline as dependent variable and 
baseline value and time (in years) as covariate, and treatment as a fixed factor and the 
interaction between treatment and time. Patient-specific intercepts and time as random effects 
assuming a bivariate normal distribution for these effects were included in the model. 
Analyses by subgroups were performed by including the respective subgroups as a fixed 
factor and the interaction with treatment. Data shown were averaged over 2 years. CI, 
confidence interval; eGFR, estimated glomerular filtration rate; NS, not significant; OD, 
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Figure 3: Effects of Semaglutide/Liraglutide Versus Placebo on Time to the First 
Persistent Reduction in eGFR of 30%, 40%, 50%, and 57% From Baseline, in the 
Pooled Population and Subgroups According to eGFR (mL/min/1.73m2) at Baseline. 
Time to persistent reduction of eGFR from baseline was analysed independently from each 
other. Subgroup analyses were performed by including subgroup as a fixed factor and the 
interaction between subgroup and treatment. CI, confidence interval; eGFR, estimated 
glomerular filtration rate; HR, hazard ratio.  
Figure 4: Effects of Semaglutide/Liraglutide Versus Placebo on Time to the First 
Persistent Reduction in eGFR of 30%, 40%, 50%, and 57% From Baseline, in the 
Pooled Population and Subgroups Defined by the Level of Albuminuria at Baseline. 
Time to persistent reduction of eGFR from baseline was analyzed independently from each 
other. Subgroup analyses were performed by including subgroup as a fixed factor and the 
interaction between subgroup and treatment. CI, confidence interval; eGFR, estimated 
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